Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 14, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gastrointestinal Stromal Tumor (GIST) - Overview 10
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 19
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment0
Assessment by Target0
Assessment by Mechanism of Action3
Assessment by Route of Administration7
Assessment by Molecule Type9
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 31
AB Science SA 31
Advanced Accelerator Applications SA 31
Ariad Pharmaceuticals Inc 32
Arog Pharmaceuticals Inc 32
ArQule Inc 32
Array BioPharma Inc 33
Ascentage Pharma Group Corp Ltd 33
Astex Pharmaceuticals Inc 34
Blueprint Medicines Corp 34
Boston Biomedical Inc 34
Calithera Biosciences Inc 35
Celldex Therapeutics Inc 35
Chipscreen Biosciences Ltd 36
Deciphera Pharmaceuticals LLC 36
Eli Lilly and Co 37
Exelixis Inc 37
F. Hoffmann-La Roche Ltd 38
Hanmi Pharmaceuticals Co Ltd 38
Horizon Pharma Plc 38
Immunicum AB 39
Jiangsu Hengrui Medicine Co Ltd 39
Loxo Oncology Inc 40
Merck & Co Inc 40
Natco Pharma Ltd 41
Nerviano Medical Sciences Srl 41
Novartis AG 42
Omeros Corp 42
Pharma Mar SA 43
Plexxikon Inc 43
Rhizen Pharmaceuticals SA 44
Taiho Pharmaceutical Co Ltd 44
Xencor Inc 45
Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 46
aldoxorubicin hydrochloride - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
amcasertib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
anagrelide hydrochloride CR - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
APG-1351 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
binimetinib - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
BLU-285 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
buparlisib hydrochloride - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
cabozantinib s-malate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
CB-839 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
CDX-0158 - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
CHMFLKIT-110 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
crenigacestat - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
crenolanib besylate - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
CS-2164 - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
DCC-2618 - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
everolimus - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
HM-95573 - Drug Profile 157
Product Description 157
Mechanism Of Action 157
R&D Progress 157
ilixadencel - Drug Profile 159
Product Description 159
Mechanism Of Action 159
R&D Progress 159
interferon gamma-1b - Drug Profile 168
Product Description 168
Mechanism Of Action 168
R&D Progress 168
larotrectinib - Drug Profile 173
Product Description 173
Mechanism Of Action 173
R&D Progress 173
masitinib - Drug Profile 180
Product Description 180
Mechanism Of Action 180
R&D Progress 180
miransertib - Drug Profile 197
Product Description 197
Mechanism Of Action 197
R&D Progress 197
NMSP-088 - Drug Profile01
Product Description01
Mechanism Of Action01
R&D Progress01
NRCAN-019 - Drug Profile02
Product Description02
Mechanism Of Action02
R&D Progress02
onalespib - Drug Profile04
Product Description04
Mechanism Of Action04
R&D Progress04
pembrolizumab - Drug Profile08
R&D Progress09
Peptide to Antagonize GRPR for Oncology - Drug Profile74
Product Description74
Mechanism Of Action74
R&D Progress74
pexidartinib hydrochloride - Drug Profile75
Product Description75
Mechanism Of Action75
R&D Progress75
PLX-9486 - Drug Profile80
Product Description80
Mechanism Of Action80
R&D Progress80
PM-184 - Drug Profile81
Product Description81
Mechanism Of Action81
R&D Progress81
ponatinib hydrochloride - Drug Profile83
Product Description83
Mechanism Of Action83
R&D Progress83
SF-1126 - Drug Profile99
Product Description99
Mechanism Of Action99
R&D Progress99
SHR-1020 - Drug Profile 302
Product Description 302
Mechanism Of Action 302
R&D Progress 302
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 304
Product Description 304
Mechanism Of Action 304
R&D Progress 304
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 305
Product Description 305
Mechanism Of Action 305
R&D Progress 305
TAS-116 - Drug Profile 306
Product Description 306
Mechanism Of Action 306
R&D Progress 306
umbralisib tosylate - Drug Profile 307
Product Description 307
Mechanism Of Action 307
R&D Progress 307
vemurafenib - Drug Profile 318
Product Description 318
Mechanism Of Action 318
R&D Progress 318
WBZ-4 - Drug Profile 326
Product Description 326
Mechanism Of Action 326
R&D Progress 326
XmAb-18087 - Drug Profile 327
Product Description 327
Mechanism Of Action 327
R&D Progress 327
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 328
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 329
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 330
Featured News & Press Releases 330
Nov 10,017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes 330
Nov 10,017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 332
Nov 01,017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 333
Sep 11,017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology017 Congress 334
Aug 31,017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the017 European Society for Medical Clinical Oncology Annual Congress 335
Aug 02,017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 336
Jun 05,017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 337
Jun 05,017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at017 American Society of Clinical Oncology Annual Meeting 339
May 18,017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the017 American Society of Clinical Oncology Annual Meeting 340
May 17,017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at017 ASCO Annual Meeting 340
Apr 03,017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 341
Nov 30,016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors 341
Nov 30,016: Results from 3 ground-breaking studies show early benefit to patients 343
Nov 16,016: Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene 346
Nov 15,016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 at8th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 346
Appendix 348
Methodology 348
Coverage 348
Secondary Research 348
Primary Research 348
Expert Panel Validation 348
Contact Us 348
Disclaimer 349

List Of Tables

List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017 11
Number of Products under Development by Companies, H2 2017 13
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Universities/Institutes, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Universities/Institutes, H2 2017 19
Number of Products by Stage and Target, H2 2017 21
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 22
Number of Products by Stage and Mechanism of Action, H2 2017 24
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 25
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 26
Number of Products by Stage and Route of Administration, H2 2017 28
Number of Products by Stage and Molecule Type, H2 2017 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2017 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H2 2017 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H2 2017 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H2 2017 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H2 2017 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2017 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H2 2017 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H2 2017 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H2 2017 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H2 2017 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2017 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H2 2017 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H2 2017 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2017 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2017 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Loxo Oncology Inc, H2 2017 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Merck & Co Inc, H2 2017 41
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H2 2017 41
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H2 2017 42
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2017 42
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H2 2017 43
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H2 2017 43
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H2 2017 44
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017 44
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 44
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xencor Inc, H2 2017 45
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2017 328
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2017 329

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available